Surveillance data reveals plateauing adolescent vaccination rates and persistent rural-urban disparities, highlighting the need for targeted clinical review.
Data from the 2025 National Immunization Survey-Teen for 18,692 adolescents aged 13-17 years were analyzed to assess trends in adolescent vaccination coverage.The 2025 CDC Child and Adolescent Immunization Schedule (updated July 2, 2025) recommended routine vaccination of persons aged 11-12 years with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap); quadrivalent meningococcal conjugate vaccine (MenACWY); and human papillomavirus (HPV) vaccine (which may be started at age 9 years).In 2025, coverage with ≥1 dose of Tdap and ≥1 dose of MenACWY decreased compared with 2024 but remained approximately 90%.HPV vaccination coverage (≥1 dose and up to date with HPV vaccination series) did not increase for the fourth consecutive year and remained lower than coverage with ≥1 dose of Tdap and ≥1 dose of MenACWY.Differences in vaccination coverage between nonmetropolitan statistical areas (mostly rural) and metropolitan statistical areas (mostly urban) persisted in 2025: coverage with ≥1 dose of HPV vaccine was 12.0 percentage points lower among adolescents living in mostly rural areas than among those living in mostly urban areas.Vaccination coverage varied by jurisdiction, with the largest variation observed for HPV vaccine.To ensure that adolescents are up to date, providers can review adolescent vaccination records, discuss recommended vaccines with families, and during all clinical encounters, administer all recommended vaccines that are due.* On October 25, 2023, the Advisory Committee on Immunization Practices (ACIP) recommended that a pentavalent MenABCWY vaccine (MenACWY-TT/MenB-FHbp) may be administered to persons aged ≥10 years when both a quadrivalent meningococcal conjugate vaccine (MenACWY) and meningococcal B vaccine (MenB) are indicated at the same visit.On April 16, 2025, ACIP recommended that a second pentavalent vaccine option (MenACWY-CRM/MenB-4C) (PENMENVY | FDA) may be administered when both MenACWY and MenB are indicated at the same visit.More information on MenABCWY is available online.Meningococcal Vaccine Recommendations | Meningococcal | CDC † Influenza vaccination is recommended for all persons aged ≥6 months.Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger; United States 2025 Influenza vaccination coverage estimates are available online.FluVaxView | CDC
No takes yet. Share an insight, caveat, or question.
Pingali et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: